Tenon Medical Reports 32% Revenue Growth in Q3 2025, Faces Operating Losses

Tenon Medical, Inc. reported its financial results for the third quarter of 2025, revealing a revenue of $1.173 million, a 32% increase from $887,000 in the same period last year. For the nine months ending September 30, 2025, the company generated $2.463 million in revenue, slightly down from $2.507 million in the prior year. The gross profit for the third quarter was $773,000, compared to $418,000 in the previous year, reflecting a gross margin of 66%, up from 47%. However, the company continues to face significant operating losses, reporting a net loss of $3.339 million for the quarter, compared to a loss of $3.184 million in Q3 2024.

The company’s operating expenses increased to $4.165 million in the third quarter, up from $3.633 million a year earlier, driven primarily by higher sales and marketing costs, which rose by 27% to $1.538 million. Research and development expenses decreased by 35% to $428,000, while general and administrative expenses increased by 25% to $2.199 million, largely due to acquisition-related costs. For the nine-month period, total operating expenses decreased to $11.267 million from $11.951 million, indicating a reduction in overall spending despite the ongoing losses.

In August 2025, Tenon Medical completed two significant acquisitions: the SImmetry Acquisition and the SIMPL Acquisition, which involved purchasing the assets of SiVantage, Inc. and SIMPL Medical, respectively. These acquisitions are expected to enhance the company’s product offerings in the sacroiliac joint fusion market. The company has focused on expanding its product line, which now includes the SImmetry SI Joint Fusion System alongside its existing Catamaran System. The acquisitions are anticipated to provide additional revenue streams and improve market share in the orthopedic device sector.

As of September 30, 2025, Tenon Medical reported total assets of $10.366 million, up from $9.843 million at the end of 2024. The company’s cash and cash equivalents decreased to $3.442 million from $6.535 million, reflecting ongoing operational cash burn. The total liabilities increased to $5.568 million, primarily due to accrued expenses and contingent consideration related to the recent acquisitions. The company has an accumulated deficit of approximately $78.5 million and continues to seek additional capital to fund its operations, indicating a need for ongoing financial support to sustain its business model.

Looking ahead, Tenon Medical anticipates that its existing cash reserves will not be sufficient to cover operational expenses for the next 12 months. The company plans to raise additional capital through public or private equity offerings, debt financing, and collaborations. The recent announcement of a private investment in public equity (PIPE) financing, expected to close on November 14, 2025, aims to raise $2.85 million, which will help bolster its financial position as it navigates the challenges of the medical device market.